In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million)
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...